SCHEMBL1998991

SCHEMBL1998991

O=C(NC1CCCC1)c1ccc2c(c1)N(S(=O)(=O)c1ccc(Cl)cc1)CCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.55
CNR2 P34972 2/20 0.55
CNR1 P21554 1/20 0.55
CPT1A P50416 5/20 0.54
CPT2 P23786 3/20 0.54
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
GAA P10253 1/20 0.52
ALDH1A1 P00352 3/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51
CPT1B Q92523 3/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
TP53 P04637 2/20 0.47
HPGD P15428 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001650 0.90 CNR1 (0.67) CYP2C9CNR2CNR1CPT1ACPT2
SCHEMBL2001876 0.90 CPT1A (0.56) CYP2C9CNR2CNR1CPT1ACPT2
SCHEMBL2001367 0.84 RORC (0.55) CNR2CNR1CPT1ANPC1RAB9A
SCHEMBL1997840 0.80 CYP2C9 (0.56) CYP2C9CPT1ACPT2CPT1BSMN1; SMN2
SCHEMBL18581858 0.75 CPT1A (0.62) CYP2C9CPT1ACPT2NPC1ALDH1A1
SCHEMBL2006093 0.74 CNR1 (0.59) CNR2CNR1CPT1ANPC1RAB9A
SCHEMBL5021967 0.73 CPT1A (0.60) CYP2C9CPT1ACPT2CPT1BMAPT
SCHEMBL750406 0.73 CPT1A (0.80) CYP2C9CPT1ACPT2CPT1B
SCHEMBL2003923 0.73 CNR1 (0.49) CNR2CNR1CPT1AGAAALDH1A1
SCHEMBL2001759 0.73 RORC (0.49) CNR2CNR1CPT1AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
WO-2009035997-A2 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CNR1, CNR2, TRPV1 CYP2C9 210/4885CNR2 2/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.